|1.||Ihan, Alojz: 1 article (01/2006)|
|2.||Stegel, Vida: 1 article (01/2006)|
|3.||Jezersek Novaković, Barbara: 1 article (01/2006)|
|4.||Kopitar, Andreja: 1 article (01/2006)|
|5.||Novaković, Srdjan: 1 article (01/2006)|
04/01/1986 - "In vivo experiments showed that treatment of mice bearing the WEHI-3B D+ tumor first with CY and three days later with the CSF inducer MVE-2, significantly increased their survival time and rendered 20% to 50% of the tumor-bearing mice disease free. "
01/01/1983 - "Late in the disease only MVE-2 introduced directly into the metastatic tumor bed by intrapleural injection proved to be effective in prolonging life span. "
01/01/1983 - "These studies indicate that both the primary and metastatic M109 tumors are sensitive to MVE-2 and suggest that the efficacy of MVE-2 treatment is largely dependent upon its distribution in the tumor-bearing mice."
01/01/1985 - "injection of MVE-2 cured 20% of the tumor-bearing mice, while repeated i.p. "
01/01/1987 - "These results warrant further study on the contribution of I-Ad+ macrophages to pyran copolymer-induced augmentation of the antitumor response in tumor vaccine-primed mice."
|2.||Neoplasm Metastasis (Metastasis)
06/01/1985 - "This high-dose regimen removed all detectable NK activity from the lung and liver, and concomitantly eliminated the metastasis-inhibiting effect of MVE-2. "
11/01/1986 - "Despite the ability of these agents to increase survival of metastases in control animals, they only slightly abrogated the antimetastatic activity of MVE-5. "
01/01/1985 - "Additionally, MVE-2 augments effector cell activity in the liver, lungs, spleen, and blood and may therefore more efficiently interfere with metastasis formation in those compartments. "
11/01/1984 - "We have previously observed that the administration of the biological response modifier (BRM) maleic anhydride divinyl ether (MVE-2) strongly augmented NK activity in lung and liver, and the augmented NK activity coincided with increased resistance to the formation of experimental metastases in these organs. "
06/01/1981 - "In contrast, MVE-2 protected mice against enhancement of lung metastases induced by exposure of the mice to these irradiations. "
08/01/1994 - "The results showed that MVE-2 protected 100% CD-1 mice from a systemic lethal challenge with GBS-090 (5 x 10(3) microorganisms/mouse) when administered 3 days before infection at dose of 50 mg kg-1. "
06/01/1993 - "Both spontaneous and BRM-induced splenic NK cell cytotoxicity were depleted for at least 5 days following treatment with the monoclonal antibody NK1.1. Antiviral protection of standard doses of MVE-2, pIC, pICLC, rmIFN-tau and CL246,738 against lethal MCMV or HSV-2 infections was not abrogated by NK cell depletion, demonstrating that NK cells are not required for BRM-induced antiviral activity against these herpesviruses. "
03/01/1985 - "At the same time, MVE-2 induced an increase in the number of cytotoxic M phi and a complete restoration within the myelopoietic lineage, which might prevent delayed side effects of CY, such as secondary infections, and might permit more intensive chemotherapeutic treatment. "
05/01/1984 - "Resident peritoneal macrophages, exudate macrophages primed by elicitation with pyran copolymer, and activated macrophages induced by chronic infection of mice with bacillus Calmette-Guerin (BCG) or elicitation with heat killed Propionibacterium acnes (P. "
03/15/1984 - "The protection of pyran copolymer pretreated mice from infection with C. "
10/01/1981 - "Administration i.v. of MVE-2 resulted in tumoristatic and tumoricidal activity in alveolar macrophages against radiolabeled B16 and Madison 109 lung carcinoma target cells. "
02/01/1977 - "Macrophage involvement in the protective effect of pyran copolymer against the Madison lung carcinoma (M109)."
07/01/1994 - "We have investigated this issue in the Lewis lung (3LL) peritoneal carcinomatosis model in which treatment with the BRM MVE-2 slows tumor growth and enhances survival. "
10/01/1981 - "BALB/c mice bearing the lung-metastasizing Madison 109 lung carcinoma footpad tumor were given MVE-2 i.v., using the same dosing regimen that induced alveolar macrophages to be tumoricidal in vitro. "
01/01/1983 - "Intraperitoneal treatment with the interferon inducer, maleic anhydride-divinyl ether copolymer (MVE), has previously been demonstrated to effectively reduce metastatic growth in the lungs and prolong survival times of BALB/c mice bearing the syngeneic Madison lung (M109) carcinoma. "
03/01/1990 - "DIVEMA showed a significant antitumor activity against colon 26 adenocarcinoma and FSaI fibrosarcoma transplanted in syngenic mice. "
06/01/1978 - "Effects of combined radiotherapy and immunotherapy with the use of pyran copolymer on murine fibrosarcoma."
06/01/1981 - "A 15,500 molecular-weight fraction of a pyran copolymer, (MVE-2) was investigated for its therapeutic efficacy against artificial lung metastases of a weakly immunogenic spontaneous fibrosarcoma (NFSa), a relatively strongly immunogenic fibrosarcoma (FSa), a moderately immunogenic spontaneous mammary carcinoma (MCa-K-, and a weakly immunogenic spontaneous mammary carcinoma (MDAH-MCa-4) syngeneic to C3Hf/Kam mice. "
04/01/1975 - "Intraperitoneal administration of pyran copolymer (pyran-2-succinic anhydride-4,5-dicarboxytetrahydro-6-methylanhydride polymer) protected C3H/HeN male mice against tumor development after intradermal challenge with cells of the transplantable, methylcholanthrene-induced, syngeneic fibrosarcoma 1038. "
|1.||Macrophage Colony-Stimulating Factor
|2.||Immunologic Factors (Immunomodulators)
|6.||Carboxymethylcellulose Sodium (Polycell)
|7.||vinyl ether (divinyl ether)
|8.||Maleic Anhydrides (Maleic Anhydride)
|1.||Drug Therapy (Chemotherapy)
|2.||Homologous Transplantation (Allograft)